Changing Epidemiological Characteristics of Hepatitis A in Zhejiang Province, China: Increased Susceptibility in Adults
Overview
Authors
Affiliations
Background: Hepatitis A is a common acute hepatitis caused by hepatitis A virus (HAV). Annually, it affects 1.4 million people worldwide. Between 1991 and 1994, HAV infections were highly endemic in Zhejiang Province (China), with 78,720 reported HAV infections per year. Hepatitis A vaccine came on the market in 1995 and was implemented for voluntary immunization. Since 2008, hepatitis A vaccine has been integrated into the national childhood routine immunization program.
Objective: To understand the current epidemiological profile of hepatitis A in Zhejiang Province since hepatitis A vaccine has been available for nearly two decades.
Methods: This study used the 2005-2014 National Notifiable Diseases Reporting System data to evaluate the incidence rate of notified hepatitis A cases in Zhejiang Province.
Results: The overall trend of incidence rate of notified hepatitis A cases significantly decreased from 2005 to 2014 (P< 0.001). During the study period, the reported incidence rate in individuals aged ≤19 years declined to the historically lowest record in 2014. Compared with individuals aged ≤19 years, those aged ≥20 years showed the highest incidence rate (P< 0.001). Majority of HAV infected cases were Laborers, accounting for approximately 70% of reported cases.
Conclusions: Childhood immunization strategy with hepatitis A vaccine seemed to be effective in decreasing notified hepatitis A incidence rate in individuals aged ≤19 years. Those aged ≥20 years were observed to be the most susceptible population. The vast majority of hepatitis A cases were notified among Laborers. Therefore, we strongly suggest that future preventive and control measures should focus more on adults, particularly Laborers, in addition to the current childhood hepatitis A vaccination programme.
Global burden and trends of viral hepatitis among women of childbearing age from 1990 to 2021.
Yang S, Zhong L, Huang L, Lin S, Li Y Front Microbiol. 2025; 16:1553129.
PMID: 40061861 PMC: 11885505. DOI: 10.3389/fmicb.2025.1553129.
Peng H, Wang Y, Wei S, Kang W, Zhang X, Cheng X Front Public Health. 2024; 12:1476748.
PMID: 39697280 PMC: 11652658. DOI: 10.3389/fpubh.2024.1476748.
The Shifting Epidemiology of Hepatitis A in the World Health Organization Western Pacific Region.
Gloriani N, de Paz-Silava S, Allison R, Takashima Y, Avagyan T Vaccines (Basel). 2024; 12(2).
PMID: 38400187 PMC: 10891653. DOI: 10.3390/vaccines12020204.
Wu Y, Wang P, Huang Y, Chen J, Chang Y, Li J BMJ Glob Health. 2024; 9(2).
PMID: 38320803 PMC: 10859990. DOI: 10.1136/bmjgh-2023-013444.
Kim S, Yoo K, Huh J J Korean Med Sci. 2022; 37(37):e287.
PMID: 36163480 PMC: 9512680. DOI: 10.3346/jkms.2022.37.e287.